EDIT Editas Medicine, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$2.62
· of 52w range
· above low
· to high
$1.6752w low
$4.5452w high
Market Cap (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Revenue (TTM)
$47M
your badges
52W Range
$2–$5
Analyst Rating
BUY
Price Target
$6
P/E
-4.0
ROE
-118.8%
Net Profit Margin
-157.3%
Your badge strip is empty — pin a metric anywhere on this page.
EDIT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.62
Market Cap (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Revenue (TTM)
$47M
ROE (TTM)
-118.8%
Debt/Equity (MRQ)
0.5
52W Range
$2–$5
EDIT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Editas Medicine, Inc. - Common Stock Company overview from Wikipedia
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees87
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$41M2016-12-31 → 2025-12-31
EPS$-1.802019-12-31 → 2025-12-31
Free Cash Flow$-166M2016-12-31 → 2025-12-31
Net margin-157.3%2018-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | EDIT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -4.05Y avg ≈-3.7 | ≈-3.7 | · | · | |
| P/S (TTM) | 5.55Y avg ≈24.2 | ≈24.2 | 11.6 | Undervalued | |
| P/B (MRQ) | 2.45Y avg ≈3.1 | ≈3.1 | 2.2 | Overvalued | |
| EV / EBITDA | -1.1 | · | · | · | |
| Price / FCF (TTM) | -2.15Y avg ≈-4.3 | ≈-4.3 | · | · | |
| Price / Cash Flow (TTM) | -2.15Y avg ≈-4.5 | ≈-4.5 | · | · | |
| EV / Revenue (TTM) | 2.1 | · | · | · | |
| EV / FCF (TTM) | -0.8 | · | · | · | |
| Price / Tangible Book | 9.45Y avg ≈3.1 | ≈3.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | EDIT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -161.4%5Y avg ≈-658.2% | ≈-658.2% | -334.4% | Top tier | |
| EBITDA Margin | -394.9%5Y avg ≈-658.2% | ≈-658.2% | -334.4% | Top tier | |
| Net Profit Margin (TTM) | -157.3%5Y avg ≈-639.3% | ≈-639.3% | -300.0% | Top tier | |
| ROA (TTM) | -33.0%5Y avg ≈-43.0% | ≈-43.0% | -47.0% | Weak | |
| ROE (TTM) | -118.8%5Y avg ≈-195.1% | ≈-195.1% | -63.2% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | EDIT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.5 | · | 0.0 | High debt | |
| Current Ratio (MRQ) | 3.25Y avg ≈5.9 | ≈5.9 | 5.6 | Low liquidity | |
| Quick Ratio (MRQ) | 3.15Y avg ≈5.8 | ≈5.8 | 4.2 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.5 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | EDIT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 25.4%5Y avg ≈33.7% | ≈33.7% | · | · | |
| Revenue CAGR 3Y | 27.2%5Y avg ≈10.1% | ≈10.1% | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | EDIT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.25Y avg ≈0.1 | ≈0.1 | 0.1 | Top tier | |
| Receivables Turnover | 2.65Y avg ≈6.1 | ≈6.1 | · | · | |
| Revenue / Employee | ≈$465.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
2.8%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.15 | $-0.28 | 45.5% |
| March 31, 2026 | May 11, 2026 | $-0.26 | $-0.27 | 3.3% |
| Dec. 31, 2025 | $-0.06 | $-0.26 | 77.2% | |
| Sept. 30, 2025 | $-0.28 | $-0.30 | 7.3% | |
| June 30, 2025 | $-0.63 | $-0.38 | -63.8% | |
| March 31, 2025 | $-0.92 | $-0.60 | -53.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $1.62 | $4.27 | $5.24 | $8.09 | $6.29 | $4.83 | $4.84 | $4.68 | $3.76 | |
| Revenue / Share | $0.46 | $0.39 | $1.03 | $0.29 | $0.38 | · | · | · | · | · | |
| Cash Flow / Share | $-1.86 | $-2.55 | $-1.74 | $-2.58 | $-2.42 | · | · | · | · | · | |
| Cash / Share | $1.50 | $1.59 | $1.51 | $2.06 | $2.97 | $2.23 | $4.38 | $2.76 | $3.29 | $5.17 | |
| EPS (TTM) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $42.0K | $6M | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $41M | $44M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $16M | $17M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $58M | $61M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-58M | $-54M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $1.0K | $235.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-56M | $-53M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | $-58M | $-54M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $211M | $169M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | $209M | $283M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | $120.0K | $713.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | $7M | $8M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | $427M | $461M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | $15M | $16M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | $36M | $35M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | $20M | $19M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | $8M | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | $7M | $6M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | $19M | $20M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | $42M | $36M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | $9M | $10M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | $116M | $115M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | $-1.02B | $-962M | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | $-4M | $-3M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $415M | $465M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | 68,761,729 | 68,718,434 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $6M | $7M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-48M | $-38M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $614.0K | $632.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $89M | $-4M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $80.0K | $367.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $41M | $-41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | -132681.0% | -840.2% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | -8.9% | -8.0% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | -11.1% | -9.9% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | 10.1 | 12.7 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | 9.9 | 12.4 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | 0.2 | 12.2 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $0.04 | · | $0.14 | $0.22 | $0.75 | · | $2.13 | $2.81 | $3.58 | · | $4.41 | $4.90 | $4.60 | $6.03 | $6.77 | |
| Revenue / Share | $0.10 | $0.03 | · | $0.08 | $0.04 | $0.06 | · | $0.00 | $0.01 | $0.01 | · | $0.07 | $0.04 | $0.14 | $0.00 | $0.09 | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $-0.58 | · | · | · | $-0.61 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.86 | $1.26 | · | $1.78 | $1.59 | $1.66 | · | $1.16 | $0.78 | $0.84 | · | $1.01 | $2.71 | $1.87 | $3.06 | $2.47 | |
| EPS (TTM) | $-0.66 | $-1.14 | · | $-2.38 | $-2.85 | $-3.04 | · | $-2.53 | $-2.33 | $-2.07 | · | $-2.70 | $-2.96 | $-3.18 | $-2.94 | $-2.70 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $47M | $39M | · | $46M | $39M | $36M | · | $62M | $67M | $69M | · | $25M | $19M | $23M | $26M | $32M | |
| Net Income TTM | $-74M | $-109M | · | $-200M | $-237M | $-251M | · | $-211M | $-193M | $-166M | · | $-195M | $-206M | $-219M | $-201M | $-184M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | $842M | $813M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.9 | -2.2 | · | -1.5 | -0.8 | -0.4 | · | -1.3 | -2.0 | -3.6 | · | -2.9 | -2.8 | -2.3 | -4.2 | -4.4 | |
| P/S | 6.7 | 6.2 | · | 7.0 | 4.9 | 2.7 | · | 4.6 | 5.7 | 8.8 | · | 25.9 | 34.8 | 21.9 | 32.8 | 25.6 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| EV / Revenue | 3.4 | 4.5 | · | 4.7 | 1.8 | -1.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -20.4% | -46.2% | · | -68.6% | -129.6% | -262.1% | · | -74.2% | -49.9% | -27.9% | · | -34.6% | -36.0% | -43.9% | -24.0% | -22.8% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M |
| Operating Margin % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M |
| Diluted EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 2.1 | 0.4 | · | · | · |
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M |
Institutional owners (13F) 236 filers · $406.3M total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
236
Value held
$406.3M
New positions
38
Exited positions
23
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 38 (-7 vs prior Q) | 23 (-3 vs prior Q) | 80 (+22 vs prior Q) | 42 (-8 vs prior Q) | +68.9M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36,000,000 | 11,111,111 | 8.86% | Shares |
| BlackRock, Inc. | $34,311,568 | 10,589,990 | 8.44% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $28,800,360 | 8,889,000 | 7.09% | Shares |
| Commodore Capital LP | $28,800,360 | 8,889,000 | 7.09% | Shares |
| ADAR1 Capital Management, LLC | $28,800,360 | 8,889,000 | 7.09% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $19,897,929 | 6,141,336 | 4.90% | Shares |
| Paradigm Biocapital Advisors LP | $18,100,665 | 5,586,625 | 4.45% | Shares |
| VANGUARD GROUP INC | $16,826,539 | 8,208,068 | 4.14% | Shares |
| Opaleye Management Inc. | $12,512,653 | 3,861,930 | 3.08% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11,658,618 | 3,598,339 | 2.87% | Shares |
| Woodline Partners LP | $11,519,810 | 3,555,497 | 2.84% | Shares |
| Vivo Capital, LLC | $11,519,010 | 3,555,250 | 2.83% | Shares |
| GordonMD Global Investments LP | $10,131,480 | 3,127,000 | 2.49% | Shares |
| GOLDMAN SACHS GROUP INC | $8,469,476 | 2,614,036 | 2.08% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $8,325,643 | 2,569,072 | 2.05% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $7,999,298 | 2,468,919 | 1.97% | Shares |
| Logos Global Management LP | $7,199,280 | 2,222,000 | 1.77% | Shares |
| STATE STREET CORP | $7,101,442 | 2,191,803 | 1.75% | Shares |
| MARSHALL WACE, LLP | $6,600,808 | 2,037,287 | 1.62% | Shares |
| D. E. Shaw & Co., Inc. | $6,159,246 | 1,901,002 | 1.52% | Shares |
| JPMORGAN CHASE & CO | $5,959,980 | 1,862,494 | 1.47% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $5,094,065 | 1,572,242 | 1.25% | Shares |
| TWO SIGMA INVESTMENTS, LP | $4,318,842 | 1,332,976 | 1.06% | Shares |
| Seven Fleet Capital Management LP | $4,310,820 | 1,330,500 | 1.06% | Shares |
| RAYMOND JAMES FINANCIAL INC | $4,273,389 | 1,318,947 | 1.05% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $3,344,111 | 1,032,133 | 0.82% | Shares |
| MACKENZIE FINANCIAL CORP | $2,844,856 | 878,042 | 0.70% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,812,424 | 868,032 | 0.69% | Shares |
| Nantahala Capital Management, LLC | $2,762,748 | 852,700 | 0.68% | Shares |
| NORTHERN TRUST CORP | $2,655,806 | 819,693 | 0.65% | Shares |
| TWO SIGMA ADVISERS, LP | $2,509,405 | 1,224,100 | 0.62% | Shares |
| UBS Group AG | $2,432,472 | 750,763 | 0.60% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,407,158 | 742,950 | 0.59% | Shares |
| Nuveen, LLC | $1,688,730 | 521,213 | 0.42% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,616,750 | 498,997 | 0.40% | Shares |
| Susquehanna Portfolio Strategies, LLC | $1,545,801 | 477,099 | 0.38% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,521,180 | 469,500 | 0.37% | Call option |
| Eversept Partners, LP | $1,486,541 | 458,809 | 0.37% | Shares |
| Casdin Capital, LLC | $1,441,800 | 445,000 | 0.35% | Shares |
| PEAK6 LLC | $1,346,029 | 415,441 | 0.33% | Shares |
| DIADEMA PARTNERS LP | $1,296,000 | 400,000 | 0.32% | Call option |
| MORGAN STANLEY | $1,108,616 | 342,165 | 0.27% | Shares |
| BIT Capital GmbH | $1,056,240 | 326,000 | 0.26% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,002,440 | 309,395 | 0.25% | Shares |
| Cubist Systematic Strategies, LLC | $994,094 | 286,482 | 0.24% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878,642 | 271,186 | 0.22% | Shares |
| Bank of New York Mellon Corp | $850,907 | 262,625 | 0.21% | Shares |
| BANK OF AMERICA CORP /DE/ | $751,119 | 231,827 | 0.18% | Shares |
| LPL Financial LLC | $748,813 | 231,115 | 0.18% | Shares |
| Erste Asset Management GmbH | $736,000 | 230,000 | 0.18% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 filings | Sept. 18, 2017 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 35 insiders · 17 officers · 17 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | Sept. 3, 2026 S | 243,189 | 0 | 4 | $-80,045 |
| MULLEN JAMES C | CEO | April 14, 2022 A | 75,898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | Feb. 9, 2021 S | 43,760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | Jan. 8, 2019 S | 1,204,966 | 0 | 0 | $0 |
| Amy Parison | SVP, Chief Financial Officer | Sept. 3, 2026 S | 13,839 | 0 | 5 | $-6,327 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | March 8, 2025 A | 112,720 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | May 11, 2023 S | 106,610 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | Feb. 4, 2019 M | 0 | 0 | 0 | $0 |
| Daniel Scott Ory | EVP, Chief Medical Officer | Sept. 8, 2026 A | · | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sept. 3, 2026 S | 61,660 | 0 | 5 | $-20,333 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Dec. 3, 2024 S | 133,354 | 0 | 0 | $0 |
| Bruce Eaton | EVP, CBO AND CTO | Dec. 5, 2023 S | 74,791 | 0 | 0 | $0 |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER | Feb. 13, 2023 S | 65,559 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | Dec. 22, 2021 A | 22,675 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | Oct. 28, 2019 A | 25,000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | March 18, 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | Feb. 7, 2018 A | 4,000 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | Director | Aug. 6, 2026 A | · | 0 | 0 | $0 |
| Elliott M. Levy | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| David Scadden | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Bernadette Connaughton | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Jessica Hopfield | Director | June 17, 2026 A | 67,700 | 0 | 0 | $0 |
| Andrew Hirsch | Director | June 17, 2026 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | Director | May 30, 2024 A | · | 0 | 0 | $0 |
| Emma Reeve | Director | May 30, 2024 A | · | 0 | 0 | $0 |
| Akshay Vaishnaw | Director | May 30, 2024 A | · | 0 | 0 | $0 |
| Boris Nikolic | Director | June 15, 2018 A | 35,000 | 0 | 0 | $0 |
| Douglas G. Cole | Director | Aug. 17, 2017 J | 3,171 | 0 | 0 | $0 |
| Kevin Bitterman | Director | June 15, 2017 A | 2,797,144 | 0 | 0 | $0 |
| Alexis Borisy | Director | June 15, 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Director | June 15, 2017 A | · | 0 | 0 | $0 |
| Kevin P Starr | 10% owner | Sept. 6, 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10% owner | Feb. 8, 2016 C | 2,649,572 | 0 | 0 | $0 |
| Charles Albright | · | Dec. 15, 2020 M | 24,907 | 0 | 0 | $0 |
| Alexandra Glucksmann | · | March 15, 2017 M | 117,788 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 17 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 39,171 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.06% | 339,728 SH | Sept. 11, 2026 | Daily |
| IBB · iShares Trust | 0.03% | 1,101,092 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 11,076 SH | Oct. 1, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 96,927 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 170,052 SH | Oct. 2, 2026 | Daily |
| IWO · iShares Trust | 0.02% | 844,017 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 575,834 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 461,967 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.01% | 2,588,297 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 47,823 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 19,230 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1,100,306 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 4,890,144 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 9,046 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,608 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 120,579 SH | Sept. 11, 2026 | Daily |
EDIT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 18 analysts
BUY
Median target
$5.00
+90.8%
5 27.8%
Strong Buy
7 38.9%
Buy
4 22.2%
Hold
2 11.1%
Sell
0 0.0%
Strong Sell
12-Month Price Target
10 analysts · 2026-10-04Mean target $5.90 +125.2%
Now
Current price $2.62
Low$1.00
Mean$5.90
High$15.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| EIKN | · | · | · | · | · | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026